Global Trends in the Proportion of Macrolide-Resistant Mycoplasma pneumoniae Infections: A Systematic Review and Meta-analysis
- PMID: 35816304
- PMCID: PMC9274321
- DOI: 10.1001/jamanetworkopen.2022.20949
Global Trends in the Proportion of Macrolide-Resistant Mycoplasma pneumoniae Infections: A Systematic Review and Meta-analysis
Abstract
Importance: The proportion of macrolide-resistant Mycoplasma pneumoniae (MRMP) infections has changed, and it differs according to geographical region.
Objective: To analyze the global patterns, including the temporal trends, regional variations, and variant types, in the proportion of MRMP infections in this systematic review and meta-anaysis.
Data sources: PubMed, Cochrane Library, and Embase databases were searched for observational studies from inception to September 10, 2021.
Study selection: Observational studies reporting the proportion of MRMP infections were screened independently by 2 authors. The presence of MRMP infection was defined as any case of M pneumoniae infection positive for any variants associated with macrolide resistance identified using respiratory samples.
Data extraction and synthesis: Data were extracted independently and in duplicate by 2 reviewers. The Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) guideline was used. Random-effects meta-analyses were used to estimate the proportion of MRMP infections.
Main outcomes and measures: The global patterns in the proportion of MRMP infections were estimated, and the temporal trends and variant types of MRMP infection with regional differences were investigated.
Results: This study included 153 studies from 150 articles (27 408 samples in 26 countries) in the meta-analysis. The global patterns in the proportion of MRMP infections showed an increasing trend with regional differences. The proportion of MRMP infections was highest in the Western Pacific regions (53.4%; 95% CI, 47.4%-60.3%), followed by the South East Asian region (9.8%; 95% CI, 0.8%-100%), the region of the Americas (8.4%; 95% CI, 6.1%-11.6%), and the European region (5.1%; 95% CI, 3.3%-8.0%). The most commonly identified variant of MRMP infection was A2063G (96.8%; 95% CI, 95.8%-97.7%), followed by A2064G (4.8%; 95% CI, 3.5%-6.7%). The proportion of MRMP infections was the highest in studies including only children (37.0%; 95% CI, 29.8%-46.1%), followed by those including only adults (15.9%; 95% CI, 6.4%-39.7%) and those including both children and adults (16.7%; 95% CI, 10.1%-27.6%).
Conclusions and relevance: This study provides global trends in the proportion of MRMP infections and suggests that strategies to prevent the spread of MRMP infection and to treat MRMP infections are needed to decrease disease burden.
Conflict of interest statement
Figures
Similar articles
-
Clinical characteristics and associated factors of macrolide-resistant mycoplasma pneumoniae pneumonia in children: a systematic review and meta-analysis.Eur J Clin Microbiol Infect Dis. 2025 Jun;44(6):1505-1522. doi: 10.1007/s10096-025-05101-z. Epub 2025 Mar 19. Eur J Clin Microbiol Infect Dis. 2025. PMID: 40106136
-
Expert consensus on the diagnosis and treatment of macrolide-resistant Mycoplasma pneumoniae pneumonia in children.World J Pediatr. 2024 Sep;20(9):901-914. doi: 10.1007/s12519-024-00831-0. Epub 2024 Aug 14. World J Pediatr. 2024. PMID: 39143259 Free PMC article. Review.
-
Macrolide-Resistant Mycoplasma pneumoniae in the United States as Determined from a National Surveillance Program.J Clin Microbiol. 2019 Oct 23;57(11):e00968-19. doi: 10.1128/JCM.00968-19. Print 2019 Nov. J Clin Microbiol. 2019. PMID: 31484701 Free PMC article.
-
Efficacy of tetracyclines and fluoroquinolones for the treatment of macrolide-refractory Mycoplasma pneumoniae pneumonia in children: a systematic review and meta-analysis.BMC Infect Dis. 2021 Sep 25;21(1):1003. doi: 10.1186/s12879-021-06508-7. BMC Infect Dis. 2021. PMID: 34563128 Free PMC article.
-
Macrolide-Resistant Mycoplasma pneumoniae Infections in Pediatric Community-Acquired Pneumonia.Emerg Infect Dis. 2020 Jul;26(7):1382-1391. doi: 10.3201/eid2607.200017. Emerg Infect Dis. 2020. PMID: 32568052 Free PMC article.
Cited by
-
Investigation of oral macrolide prescriptions in Japan using a retrospective claims database, 2013-2018.PLoS One. 2023 Jun 22;18(6):e0287297. doi: 10.1371/journal.pone.0287297. eCollection 2023. PLoS One. 2023. PMID: 37347735 Free PMC article. Review.
-
Effectiveness of the six-step approach guided online training program to improve knowledge of Mycoplasma pneumoniae pneumonia among pediatricians: a pretest-posttest study.Transl Pediatr. 2024 May 31;13(5):760-769. doi: 10.21037/tp-24-53. Epub 2024 May 24. Transl Pediatr. 2024. PMID: 38840684 Free PMC article.
-
An exceptionally large wave of M. pneumoniae infections among children in Tianjin post COVID-19 pandemic.Transl Pediatr. 2024 Oct 1;13(10):1703-1710. doi: 10.21037/tp-24-228. Epub 2024 Oct 28. Transl Pediatr. 2024. PMID: 39524400 Free PMC article.
-
A randomized controlled non-inferiority trial of placebo versus macrolide antibiotics for Mycoplasma pneumoniae infection in children with community-acquired pneumonia: trial protocol for the MYTHIC Study.Trials. 2024 Oct 3;25(1):655. doi: 10.1186/s13063-024-08438-6. Trials. 2024. PMID: 39363201 Free PMC article.
-
Characterizing the epidemiology of Mycoplasma pneumoniae infections in China in 2022-2024: a nationwide cross-sectional study of over 1.6 million cases.Emerg Microbes Infect. 2025 Dec;14(1):2482703. doi: 10.1080/22221751.2025.2482703. Epub 2025 Apr 6. Emerg Microbes Infect. 2025. PMID: 40146610 Free PMC article.
References
-
- Lee E, Kim CH, Lee YJ, et al. ; Pneumonia and Respiratory Disease Study Group of Korean Academy of Pediatric Allergy and Respiratory Disease . Annual and seasonal patterns in etiologies of pediatric community-acquired pneumonia due to respiratory viruses and Mycoplasma pneumoniae requiring hospitalization in South Korea. BMC Infect Dis. 2020;20(1):132. doi:10.1186/s12879-020-4810-9 - DOI - PMC - PubMed